Anthem Biosciences Limited (BOM:544449)
India · Delayed Price · Currency is INR 808.75
+25.25 (3.22%)
At close: Jul 31, 2026
Anthem Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 20,023 | 21,243 | 18,446 | 14,194 | 10,569 | 12,313 |
Other Revenue | 49.88 | 49.87 | 56.02 | 8 | 9.82 | 95.09 |
| 20,073 | 21,293 | 18,502 | 14,202 | 10,579 | 12,408 | |
Revenue Growth | -2.18% | 15.09% | 30.28% | 34.24% | -14.74% | 12.24% |
Cost of Revenue | 7,696 | 8,543 | 7,815 | 6,254 | 3,574 | 4,270 |
Gross Profit | 12,377 | 12,750 | 10,687 | 7,948 | 7,005 | 8,137 |
Selling, General & Admin | 2,916 | 2,848 | 2,623 | 1,844 | 1,540 | 1,379 |
Other Operating Expenses | 1,444 | 1,476 | 1,287 | 1,039 | 1,103 | 982.96 |
Operating Expenses | 5,737 | 5,665 | 4,804 | 3,702 | 3,280 | 2,940 |
Operating Income | 6,640 | 7,085 | 5,882 | 4,246 | 3,725 | 5,197 |
Interest Expense | -58.18 | -65.41 | -100.16 | -92.76 | -82.01 | -115.6 |
Interest & Investment Income | 792.7 | 792.7 | 647 | 408.62 | 290.99 | 95.76 |
Currency Exchange Gain (Loss) | 583.7 | 583.7 | 73.42 | 146.18 | 128.89 | 133.26 |
Other Non Operating Income (Expenses) | 15.6 | -5.14 | -5.1 | -1.86 | 223.59 | 16.62 |
EBT Excluding Unusual Items | 7,974 | 8,391 | 6,498 | 4,706 | 4,286 | 5,327 |
Gain (Loss) on Sale of Investments | 95.98 | 95.98 | 75.77 | 71.8 | 68.97 | 135.99 |
Gain (Loss) on Sale of Assets | -0.28 | -0.28 | -4.64 | -4.35 | -0.03 | -1.84 |
Other Unusual Items | -243.91 | -243.91 | - | - | 618.02 | - |
Pretax Income | 7,826 | 8,242 | 6,569 | 4,773 | 4,973 | 5,461 |
Income Tax Expense | 2,066 | 2,324 | 2,056 | 1,100 | 1,121 | 1,406 |
Net Income | 5,759 | 5,918 | 4,513 | 3,673 | 3,852 | 4,055 |
Net Income to Common | 5,759 | 5,918 | 4,513 | 3,673 | 3,852 | 4,055 |
Net Income Growth | 14.12% | 31.14% | 22.86% | -4.64% | -5.02% | 49.48% |
Shares Outstanding (Basic) | 562 | 561 | 559 | 567 | 570 | 570 |
Shares Outstanding (Diluted) | 570 | 567 | 562 | 567 | 570 | 570 |
Shares Change | 1.42% | 1.03% | -0.96% | -0.61% | - | 4.33% |
EPS (Basic) | 10.24 | 10.55 | 8.07 | 6.48 | 6.75 | 7.11 |
EPS (Diluted) | 10.11 | 10.43 | 8.04 | 6.48 | 6.75 | 7.11 |
EPS Growth | 12.46% | 29.73% | 24.11% | -4.03% | -5.04% | 43.27% |
Free Cash Flow | - | 6,333 | 93.43 | -1,499 | 1,171 | 1,771 |
Free Cash Flow Per Share | - | 11.16 | 0.17 | -2.64 | 2.05 | 3.10 |
Dividend Per Share | - | 2.000 | - | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 61.66% | 59.88% | 57.76% | 55.96% | 66.21% | 65.58% |
Operating Margin | 33.08% | 33.27% | 31.79% | 29.89% | 35.21% | 41.89% |
Profit Margin | 28.69% | 27.79% | 24.39% | 25.86% | 36.41% | 32.68% |
Free Cash Flow Margin | - | 29.74% | 0.51% | -10.55% | 11.06% | 14.27% |
EBITDA | 8,068 | 8,403 | 6,761 | 5,050 | 4,358 | 5,763 |
EBITDA Margin | 40.19% | 39.46% | 36.54% | 35.56% | 41.19% | 46.45% |
D&A For EBITDA | 1,428 | 1,318 | 878.74 | 804.85 | 633.27 | 566.06 |
EBIT | 6,640 | 7,085 | 5,882 | 4,246 | 3,725 | 5,197 |
EBIT Margin | 33.08% | 33.27% | 31.79% | 29.89% | 35.21% | 41.89% |
Effective Tax Rate | 26.40% | 28.20% | 31.30% | 23.05% | 22.54% | 25.74% |
Revenue as Reported | 21,602 | 22,801 | 19,303 | 14,831 | 11,340 | 12,802 |
Advertising Expenses | - | 12.07 | 15.62 | 10.62 | 5.35 | 1.17 |